37660-64-3

Basic information

• Product Name: 4,6-dichloro-3-nitropyridin-2-aMine
• Synonyms: 4,6-dichloro-3-nitropyridin-2-aMine;2-AMino-4,6-dichloro-3-nitro-pyridine;4,6-Dichloro-3-nitro-2-pyridinamine
• CAS NO: 37660-64-3
• Molecular Formula: C5H3Cl2N3O2
• Molecular Weight: 208.00222
• Mol File: 37660-64-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 366.1±37.0 °C(Predicted)
• Appearance: /
• Density: 1.723±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: -2.71±0.50(Predicted)
• CAS DataBase Reference: 4,6-dichloro-3-nitropyridin-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-dichloro-3-nitropyridin-2-aMine(37660-64-3)
• EPA Substance Registry System: 4,6-dichloro-3-nitropyridin-2-aMine(37660-64-3)

Safety Data

• Hazardous Substances Data: 37660-64-3(Hazardous Substances Data)

Usage

Description

4,6-dichloro-3-nitropyridin-2-aMine is an organic compound characterized by the presence of two chlorine atoms at the 4th and 6th positions and a nitro group at the 3rd position on a pyridine ring. It also features an amine group at the 2nd position, which contributes to its reactivity and potential applications in various chemical processes.

Uses

Used in Pharmaceutical Industry:
4,6-dichloro-3-nitropyridin-2-aMine is used as a reagent for the preparation of mTOR inhibitors. These inhibitors are important in the development of drugs targeting the mTOR pathway, which plays a crucial role in regulating cell growth, proliferation, and survival. By inhibiting the mTOR pathway, these drugs can potentially treat various diseases, including cancer and certain genetic disorders.

Upstream product

• 116632-24-7 2-amino-4,6-dichloropyridine 

Downstream Products

• 24484-99-9 4,6-dichloropyridine-2,3-diamine 

Relevant articles and documents

Design, synthesis and biological evaluation of novel 3H-imidazole [4,5-b] pyridine derivatives as selective mTOR inhibitors

A series of 3H-imidazo [4,5-b] pyridines derivatives were designed and synthesized as selective mTOR inhibitors. The systematic optimization of the molecules resulted in the identification of two compounds 10d and 10n with nanomolar mTOR inhibitory activity and selectivity over PI3Kα. Besides, compounds 10d and 10n demonstrated attractive potency against human breast cancer cells (MCF-7) and human ovarian cancer cell (A2780).

2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE

Substituted benzimidazole and 3H-imidazo[4,5-b]pyridines or formula I: where X and Y respectively are selected from: (i) N and N; and (ii) N and CR4; A2 is selected from:, a C5 heteroarylene group, containing 2 or 3 ring heteroatoms, where the bonds to L1 and the core are β to one another; L1 is selected from: (i)A1-O-CH2-A2; (ii)A1-CH2-O-A2; (iii)A1-C(=O)-NH-A2; (iv)A1-CH(OH)-A2; (v)A1-CH2-NH-C(=O)-A2; (vi) A1-S-CH2-A2; (vii)A1- CH2-S-A2; (viii)A1-CH2-A2; and (ix)A1-CH(CH3)-O-A2; A1 is phenyl, optionally substituted by F or CF3; their use as pharmaceuticals, and in particular, in treating cancer and hemoglobinopathies.